Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Tamar

Nijsten

,

PhD

Principal Investigator
Erasmus MC
Rotterdam
,
Netherlands
Request an Update
Prof. Dr. Tamar Nijsten completed his medical school, dermatology residency, and defended his PhD at the University of Antwerp (Belgium). During his PhD in dermato-epidemiology, he was supervised by Prof. Dr. Robert Stern (Harvard Medical School). In the following years, Tamar established a dermato-epidemiology group at the Department of Dermatology Erasmus MC (Rotterdam, The Netherlands), resulting in a full professorship in dermatology in 2012 and a chair position in 2014. He has been President of the Dutch Society of Dermatology for four years. Since 2019, he has been the chair of the Erasmus MC Cancer Institute and the Clinical Director of the Children’s Hospital Sophia at the Erasmus MC.

The dermato-epidemiology research group of Tamar Nijsten consists of more than a dozen PhD students, several post-docs, and academic dermatologists. They apply epidemiology, public health, and clinical research principles on various skin conditions ranging from psoriasis, and varicose veins, to skin aging and cancer. The data sources are nationally routinely collected pharmacy and claim data, national cancer registry, population-based cohorts, or clinical cohorts. The goal has always been to deliver high-quality research introducing new concepts and methodologies to directly improve patient care and contribute to better organization of care.

Tamar Nijsten published over 375 peer-reviewed international papers in 2020 (H-index 60 – 80). He has given invited lectures at many international meetings, including the European Academy of Dermatology and Venereology (EADV), the European Society for Dermatological Research (ESDR), and the Society for Investigative Dermatology (SID), and at numerous national society meetings. He has received multiple grants from The Netherlands Organisation for Health Research and Development (ZonMw), including a personal Vidi grant in 2010. He was section editor of epidemiology for eight years for the Journal of Investigative Dermatology and holds this position currently for the British Journal of Dermatology.
Last Updated:
08/14/2023

Featured

Blog

Focus on Psoriasis: A Report from the 33rd Annual European Academy of Dermatology and Venereology (EADV) Congress.

The 33rd Annual EADV Congress in Amsterdam featured updates on psoriasis care, including highlights from the IPC…

Read More

Blog

IPC 2023 Think Tank Meeting Report Published in JID Innovations.

Read key highlights from the 2023 International Psoriasis Council (IPC) Think Tank Meeting, summarizing the evolving…

Read More

Event

Symposium: Data Driven Care in Psoriasis.

EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY (EADV) | AMSTERDAM, NETHERLANDS Program chairs: Lone Skov, Denmark and…

September 25, 2024
Learn More or Register

Video

Big Data and Implications for Psoriasis.

Dr. Tamar Nijisten discusses big data and its current and future implications for psoriasis research.

Watch Video

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026